HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate-Palmolive

This article was originally published in The Rose Sheet

Executive Summary

Colgate toothpaste marketer is allocating 12 percent to 15 percent of its media spending toward digital media in certain developed regions, CEO Ian Cook states during a session of the May 28 Sanford C. Bernstein Strategic Decisions Conference. The firm says it is using a variety of social networking activities to promote brands such as Colgate Wisp disposable toothbrush in order to connect with consumers. Company also is launching educational sites, such as ColgateOralCare.com, which links consumers to 500 articles related to oral care. The efforts have significantly boosted visits to its branded sites, Cook notes. Colgate has said it would use ads to create an emotional connection with consumers (1"The Rose Sheet" Feb. 2, 2009, p. 5)

You may also be interested in...



Colgate Seizes Chance To Reconnect With Consumers In Sluggish Ad Market

Colgate-Palmolive is capitalizing on a slumping ad market by purchasing media at a lower cost and launching campaigns that strengthen its emotional connection with consumers, the firm reported during an analyst meeting Jan. 29

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel